NCT02893488 - Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 1, 2016

Primary Completion Date

November 1, 2016

Study Completion Date

November 25, 2016

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG

DTG/ABC/3TC FDC DISPERSIBLE TABLET

DTG/ABC/3TC FDC dispersible tablet

DRUG

EPZICOM (ABC/3TC)

"EPZICOM will be available as orange, film coated, modified capsule shaped tablets, debossed with GS FC2 on one side."

DRUG

TIVICAY (DTG)

TIVICAY will be available as white, round, biconvex tablets

Trial Locations (1)

GSK Investigational Site, Overland Park